Age-Adjusted D-Dimer Cutoffs: How ADJUST-PE Changed Who Gets a Scan

The short answer

The 2014 ADJUST-PE study prospectively tested a simple rule: in patients 50 and older with a low or moderate pretest probability, use age times 10 as the D-dimer cutoff instead of a flat 500. It let more people skip CT imaging while missing very few clots over three months. That study, published in JAMA by Marc Righini and colleagues, is the reason age-adjusted D-dimer now appears in emergency and hematology practice worldwide.

Why a flat cutoff fails older patients

D-dimer is a breakdown product of clot. When a suspected pulmonary embolism (PE) is being worked up, a normal D-dimer in a patient who is already unlikely to have a clot is reassuring enough to skip a CT pulmonary angiogram. That is the whole point of the test: it is good at ruling PE out, not at ruling it in.

The problem is that D-dimer rises with age, inflammation, pregnancy, cancer, and recent surgery, all on its own. Use a single threshold of 500 micrograms per liter for everyone, and older patients keep landing just above it. Their D-dimer is "positive" not because they have a clot but because they are 78 years old. The result is a flood of CT scans that come back clean, each one carrying contrast exposure, radiation, cost, and the occasional incidental finding that starts its own cascade of worry and testing.

The proposed fix was almost suspiciously simple. For anyone 50 or older, multiply their age by 10 and use that as the cutoff. A 60-year-old gets a threshold of 600, a 75-year-old gets 750. Below your personal number, PE is considered excluded without imaging.

What ADJUST-PE actually measured

The appeal of a simple rule is not evidence that it is safe. The question that matters is whether raising the threshold lets real clots slip through. ADJUST-PE was designed to answer exactly that.

It was a multicenter, multinational prospective management study, run across 19 centers in Belgium, France, the Netherlands, and Switzerland between 2010 and 2013, enrolling 3,346 patients with suspected PE. A management study is the honest way to test a rule like this. Investigators applied the age-adjusted cutoff, and crucially, patients who fell below their personal threshold were left untreated and followed for three months to see how many later turned up with a venous thromboembolism. If the rule were unsafe, those missed clots would surface as the study's failure rate.

Two numbers define the result. First, the yield. Among patients 75 and older with a nonhigh clinical probability, the flat 500 cutoff excluded PE in only about 6 percent of them. The age-adjusted cutoff pushed that to roughly 30 percent, an increase of 157 patients in that older subgroup alone who could safely avoid a scan. That is the benefit: fewer scans, concentrated exactly in the group the old cutoff served worst.

Second, the cost of that benefit. Among the 331 patients who had a D-dimer between 500 and their higher age-adjusted cutoff and were sent home without imaging or anticoagulation, exactly one had a symptomatic venous thromboembolism over the next three months. That is a failure rate of 0.3 percent, with a 95 percent confidence interval running from 0.1 percent to 1.7 percent.

Reading the trade-off honestly

Those two figures are the trade-off, and both halves deserve attention. The 0.3 percent failure rate sits comfortably inside what the field accepts for a rule-out strategy, and it is in the same range clinicians already tolerate after a negative CT scan. This is not a shortcut that trades safety for convenience; it is a recalibration that removes scans which were never adding much.

But look at that confidence interval before calling the question closed. The upper bound of 1.7 percent exists because a single event in 331 patients cannot pin down the true risk tightly. The point estimate is reassuring; the interval is a reminder that the rule was validated on a specific population and should be read as such.

That population is the fine print. Age-adjustment applies only to patients 50 and older, and only when clinical judgment has already placed them at low or moderate pretest probability using a structured tool such as the Wells or revised Geneva score. It was not tested as a standalone test for high-probability patients, and it does not replace the clinical assessment that comes first. A high pretest probability still points toward imaging regardless of the D-dimer number, because in that setting a normal D-dimer no longer carries enough weight to rule out.

There are also groups the trial does not speak to cleanly. Pregnancy, active cancer, and other high-baseline states each change how D-dimer behaves, and the age-times-10 rule was not designed to settle those cases. This is where a validated rule ends and individual clinical reasoning begins.

This article is educational and not medical advice; decisions about testing for a suspected clot belong to a patient and their own clinician, who can weigh the pretest probability and the specific circumstances.

Why this kind of evidence is worth understanding

The strength of ADJUST-PE is its design as much as its result. A retrospective look at old records could have suggested the age-adjusted cutoff was fine; only a prospective study that actually withheld imaging and then counted the clots that appeared can show that withholding was safe. The direction of the finding is clear and consistent: meaningfully fewer scans, with a failure rate that stayed low across the studied population. The honest caveats are the confidence interval width and the boundaries of who was studied.

Later guidance from professional bodies, including the 2019 European Society of Cardiology guidelines for acute pulmonary embolism, has folded age-adjusted D-dimer into diagnostic pathways for suspected PE on the strength of this and corroborating work, which is what a well-built management study is supposed to earn. A rule that fits on a sticky note earned its place not because it was clever but because someone measured what happened when patients trusted it.